Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Sales | 219,750 | 74,908 | 89,912 | 47,159 | 41,097 |
| Cost of Goods | 25,062 | 1,802 | N/A | N/A | N/A |
| Gross Profit | 194,688 | 73,106 | 89,912 | 47,159 | 41,097 |
| Operating Expenses | 1,134,181 | 888,581 | 590,000 | 471,746 | 337,105 |
| Operating Income | -939,431 | -814,673 | -500,088 | -424,587 | -296,008 |
| Other Income | 54,178 | 53,999 | 9,214 | 14,479 | 5,935 |
| Pre-tax Income | -885,253 | -760,674 | -490,874 | -410,108 | -290,073 |
| Income Tax | 863 | 823 | N/A | N/A | N/A |
| Net Income Continuous | -886,116 | -761,497 | -490,874 | -410,108 | -290,073 |
| Net Income | $-886,116 | $-761,497 | $-490,874 | $-410,108 | $-290,073 |
| EPS Basic Total Ops | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 |
| EPS Basic Continuous Ops | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 |
| EPS Diluted Total Ops | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 |
| EPS Diluted Continuous Ops | -8.11 | -7.57 | -5.42 | -4.79 | -3.45 |
| EPS Diluted Before Non-Recurring Items | -8.11 | N/A | N/A | N/A | N/A |
| EBITDA(a) | $-885,063 | $-799,425 | $-488,190 | $-409,457 | $-276,958 |